Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial

Huiping Li, Jieqiong Liu, Quchang Ouyang, Shusen Wang, Yaxin Liu, Yuee Teng, Xiaojia Wang, Jing Cheng, Zhongsheng Tong, Tao Sun, Min Yan, Xin Zhou, Fanfan Li, Jianyun Nie, Zhi‐Ming Shao, Changsheng Ye, Yongsheng Wang, Xiaohong Wu, Zhihua Li, Yudong Wu, Huihua Xiong, Hui Li, Lu Gan, Zhaofeng Niu, Juliang Zhang, Qingyuan Zhang, Yueyin Pan, Xinhong Wu, Yi Zhang, Weimin Xie, Yu Xiao, Jinnan Gao, Huadong Zhao, Yongmei Yin, Zhiying Qian, Sanyuan Sun, Hongwei Zhang, Kun Wang, Jinsong Lu, Yong Li, Xinshuai Wang, Xinfeng Yang, Yuting Wang, Quanren Wang, Erwei Song